| 41 | 0 | 47 |
| 下载次数 | 被引频次 | 阅读次数 |
由Syndecan-2基因（SDC2）编码的跨膜蛋白在肿瘤发展中扮演着复杂多变的角色，其在不同的肿瘤及不同情况下，作用可表现为促进肿瘤或者抑制肿瘤的作用，甚至在一定情况下兼具两面性。值得注意的是，基于SDC2甲基化的检测技术已成功应用于结直肠癌的无创筛查，并在临床实践中显示出高度的敏感性。这使得SDC2成为一个极具前景的新型生物标志物和潜在的治疗靶点，其转化医学价值日益凸显。文章系统梳理了SDC2基因在肿瘤中的这种双重功能及其临床应用前景，希望能为临床诊疗工作提供理论基础和实用参考。
Abstract：The transmembrane protein encoded by the syndecan-2 gene(SDC2) plays a multifaceted and context-dependent role in tumor development. Its function can manifest as either promoting or inhibiting tumor progression, or even exhibiting dual characteristics under specific conditions. Notably, detection technology based on SDC2 methylation has been successfully applied to the non-invasive screening of colorectal cancer and has demonstrated high sensitivity in clinical practice. This makes SDC2 a highly promising novel biomarker and a potential therapeutic target, with its translational medical value becoming increasingly prominent. This article comprehensively reviews and synthesizes this dual functionality of the SDC2 gene in tumors and its clinical application prospects, aiming to provide a theoretical foundation and practical reference for clinical diagnosis and treatment.
[1]Bernfield M, Kokenyesi R, Kato M, et al. Biology of the syndecans:a family of transmembrane heparan sulfate proteoglycans[J]. Annu Rev Cell Biol, 1992, 8:365-393. DOI:10.1146/annurev.cb.08.110192.002053.
[2]Mytilinaiou M, Nikitovic D, Berdiaki A, et al. Emerging roles of syndecan 2 in epithelial and mesenchymal cancer progression[J]. IUBMB Life, 2017, 69(11):824-833.DOI:10.1002/iub.1678.
[3]Czarnowski D. Syndecans in cancer:a review of function,expression, prognostic value, and therapeutic significance[J]. Cancer Treat Res Commun, 2021, 27:100312. DOI:10.1016/j.ctarc.2021.100312.
[4]Jang B, Jung H, Choi S, et al. Syndecan-2 cytoplasmic domain up-regulates matrix metalloproteinase-7expression via the protein kinase Cγ-mediated FAK/ERK signaling pathway in colon cancer[J]. J Biol Chem,2017, 292(39):16321-16332. DOI:10.1074/jbc.M117.793752.
[5]Kim S, Yang H, Cho S, et al. Correlation of syndecan gene amplification with metastatic potential and clinical outcomes in carcinomas[J]. Am J Physiol Cell Physiol,2024, 327(2):C380-C386. DOI:10.1152/ajpcell. 00270.2024.
[6]Choi S, Kim Y, Park H, et al. Syndecan-2overexpression regulates adhesion and migration through cooperation with integrin alpha2[J]. Biochem Biophys Res Commun, 2009, 384(2):231-235. DOI:10.1016/j.bbrc.2009.04.093.
[7]Vicente CM, Ricci R, Nader HB, et al. Syndecan-2 is upregulated in colorectal cancer cells through interactions with extracellular matrix produced by stromal fibroblasts[J]. BMC Cell Biol, 2013, 14:25. DOI:10.1186/1471-2121-14-25.
[8]Jang B, Jung H, Chung H, et al. Syndecan-2 enhances E-cadherin shedding and fibroblast-like morphological changes by inducing MMP-7 expression in colon cancer cells[J]. Biochem Biophys Res Commun, 2016, 477(1):47-53. DOI:10.1016/j.bbrc.2016.06.019.
[9]Kwon MJ, Kim Y, Choi Y, et al. The extracellular domain of syndecan-2 regulates the interaction of HCT116 human colon carcinoma cells with fibronectin[J]. Biochem Biophys Res Commun, 2013, 431(3):415-420. DOI:10.1016/j.bbrc.2012.12.155.
[10]Lee H, Kim Y, Choi Y, et al. Syndecan-2 cytoplasmic domain regulates colon cancer cell migration via interaction with syntenin-1[J]. Biochem Biophys Res Commun, 2011, 409(1):148-153. DOI:10.1016/j.bbrc.2011.04.135.
[11]Choi Y, Kim H, Chung H, et al. Syndecan-2 regulates cell migration in colon cancer cells through Tiam1-mediated Rac activation[J]. Biochem Biophys Res Commun, 2010, 391(1):921-925. DOI:10.1016/j.bbrc.2009.11.165.
[12]Yang Y, Cao YL, Wang WH, et al. Syndecan-2modulates the YAP pathway in epithelial-tomesenchymal transition-related migration, invasion, and drug resistance in colorectal cancer[J]. Heliyon, 2023, 9(10):e20183. DOI:10.1016/j.heliyon.2023.e20183.
[13]Hua R, Zhang Y, Yan X, et al. Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway[J]. Acta Biochim Biophys Sin(Shanghai), 2021, 53(11):1547-1557. DOI:10.1093/abbs/gmab124.
[14]Jang B, Kim A, Lee Y, et al. Substituted syndecan-2-derived mimetic peptides show improved antitumor activity over the parent syndecan-2-derived peptide[J].Int J Mol Sci, 2022, 23(11):5888. DOI:10.3390/ijms23115888.
[15]Min S, Jang B, Yun JH, et al. Anticancer effect of a single-chain variable fragment against pro-matrix metalloproteinase-7 in colon cancer[J]. Matrix Biol,2025, 135:125-134. DOI:10.1016/j. matbio. 2024.12.009.
[16]Lee S, Jang B, Hwang J, et al. Everolimus exerts anticancer effects through inhibiting the interaction of matrix metalloproteinase-7 with syndecan-2 in colon cancer cells[J]. Am J Physiol Cell Physiol, 2024, 326(4):C1067-c1079. DOI:10.1152/ajpcell.00669.2023.
[17]Long L, Sun Q, Yang F, et al. Significance of SDC2 and NDRG4 methylation in stool for colorectal cancer diagnosis[J]. Clin Biochem, 2024, 124:110717. DOI:10.1016/j.clinbiochem.2024.110717.
[18]燕普，常小伟，张永康. FOXO3联合XPNPEP2和MMP-14对结直肠癌不良预后的预测分析[J].中国肿瘤临床与康复，2021, 28(10):1169-1172. DOI:10.13455/j.cnki.cjcor.2021.10.05.
[19]Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy:turning past failures into future successes[J]. Mol Cancer Ther, 2018, 17(6):1147-1155. DOI:10.1158/1535-7163.Mct-17-0646.
[20]Yue C, Zhang Y, Wang Y, et al. The application value of syndecan-2 gene methylation for colorectal cancer diagnosis:a clinical study and meta-analyses[J]. Front Med(Lausanne), 2022, 9:753545. DOI:10.3389/fmed.2022.753545.
[21]Barták BK, Kalmár A, Péterfia B, et al. Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples[J]. Epigenetics, 2017, 12(9):751-763. DOI:10.1080/15592294.2017.1356957.
[22]Khabbazpour M, Tat M, Karbasi A, et al. Advances in blood DNA methylation-based assay for colorectal cancer early detection:a systematic updated review[J].Gastroenterol Hepatol Bed Bench, 2024, 17(3):225-240. DOI:10.22037/ghfbb.v17i3.2978.
[23]Orosco A, FromiguéO, Bazille C, et al. Syndecan-2affects the basal and chemotherapy-induced apoptosis in osteosarcoma[J]. Cancer Res, 2007, 67(8):3708-3715. DOI:10.1158/0008-5472.Can-06-4164.
[24]Modrowski D, Orosco A, Thévenard J, et al. Syndecan-2overexpression induces osteosarcoma cell apoptosis:Implication of syndecan-2 cytoplasmic domain and JNK signaling[J]. Bone, 2005, 37(2):180-189. DOI:10.1016/j.bone.2005.04.010.
[25]Marion A, DieudonnéFX, Pati?o-Garcia A, et al.Calpain-6 is an endothelin-1 signaling dependent protective factor in chemoresistant osteosarcoma[J]. Int J Cancer, 2012, 130(11):2514-2525. DOI:10.1002/ijc.26246.
[26]DieudonnéFX, Marion A, Marie PJ, et al. Targeted inhibition of T-cell factor activity promotes syndecan-2expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice[J]. J Bone Miner Res, 2012, 27(10):2118-2129. DOI:10.1002/jbmr.1650.
[27]DieudonnéFX, Marion A, Ha?E, et al. High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells[J]. Cancer Res,2010, 70(13):5399-5408. DOI:10.1158/0008-5472.Can-10-0090.
[28]Zhao F, Pu Y, Cui M, et al. MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene[J]. Cancer Cell Int, 2017, 17:100. DOI:10.1186/s12935-017-0470-2.
[29]You L, Dou Y, Zhang Y, et al. SDC2 Stabilization by USP14 Promotes Gastric Cancer Progression through Cooption of PDK1[J]. Int J Biol Sci, 2023, 19(11):3483-3498. DOI:10.7150/ijbs.84331.
[30]Wang R, Song S, Qin J, et al. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression[J]. Cancer Cell, 2023, 41(8):1407-1426.e9.DOI:10.1016/j.ccell.2023.06.005.
[31]Sung JY, Cheong JH, Shin K, et al. A subtype of cancerassociated fibroblast expressing syndecan-2(SDC2)predicts survival and immune checkpoint inhibitor response in gastric cancer[J]. Clin Transl Med, 2024, 14(12):e70079.DOI:10.1002/ctm2.70079.
[32]Yang X, Chen L, Mao Y, et al. Progressive and prognostic performance of an extracellular matrixreceptor interaction signature in gastric cancer[J]. Dis Markers, 2020, 2020:8816070. DOI:10.1155/2020/8816070.
[33]Lin W, Tang L, Zhuo C, et al. scRNA-Seq analysis revealed CAFs regulating HCC cells via PTN signaling[J]. J Hepatocell Carcinoma, 2024, 11:2269-2281.DOI:10.2147/jhc.S493675.
[34]Huang X, Xiao DW, Xu LY, et al. Prognostic significance of altered expression of SDC2 and CYR61 in esophageal squamous cell carcinoma[J]. Oncol Rep,2009, 21(4):1123-1129. DOI:10.3892/or_00000332.
[35]Li XJ, Zhang QQ, Li J, et al. Establishment of esophageal squamous carcinoma cell lines with different invasive metastatic potential and differential gene screening[J]. J Physiol Pharmacol, 2022, 73(4)10.26402/jpp.2022.4.02. DOI:10.26402/jpp.2022.4.02.
[36]Luo Q, Wu X, Nan Y, et al. TRIM32/USP11 balances ARID1A stability and the oncogenic/tumor-suppressive status of squamous cell carcinoma[J]. Cell Rep, 2020,30(1):98-111.e5. DOI:10.1016/j.celrep.2019.12.017.
[37]Kousidou O, Berdiaki A, Kletsas D, et al. Estradiolestrogen receptor:a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells[J]. Mol Oncol, 2008, 2(3):223-232. DOI:10.1016/j.molonc.2008.06.002.
[38]Loftus PG, Watson L, Deedigan LM, et al. Targeting stromal cell Syndecan-2 reduces breast tumour growth,metastasis and limits immune evasion[J]. Int J Cancer,2021, 148(5):1245-1259.DOI:10.1002/ijc.33383.
[39]Baqai U, Purwin TJ, Bechtel N, et al. Multi-omics profiling shows BAP1 loss is associated with upregulated cell adhesion molecules in uveal melanoma[J]. Mol Cancer Res, 2022, 20(8):1260-1271. DOI:10.1158/1541-7786.Mcr-21-0657.
[40]Jung H, Oh ES. FK506 positively regulates the migratory potential of melanocyte-derived cells by enhancing syndecan-2 expression[J]. Pigment Cell Melanoma Res,2016, 29(4):434-443. DOI:10.1111/pcmr.12480.
[41]Lee J H, Park H, Chung H, et al. Syndecan-2 regulates the migratory potential of melanoma cells[J]. J Biol Chem, 2009, 284(40):27167-27175.DOI:10.1074/jbc.M109.034678.
[42]Xie H, Wei M, Yao L, et al. The significance of human papillomavirus receptors related genetic variants in cervical cancer screening[J]. Microbiol Spectr, 2023, 11(4):e0511722.DOI:10.1128/spectrum.05117-22.
[43]Mukherjee A, Ye Y, Wiener HW, et al. Variations in genes Encoding human papillomavirus binding receptors and susceptibility to cervical precancer[J]. Cancer Epidemiol Biomarkers Prev, 2023, 32(9):1190-1197.DOI:10.1158/1055-9965.Epi-23-0300.
[44]姚雪芹，肖雪莲，罗其英，等. SDC2表达调控铁死亡参与宫颈癌发生的作用及机制[J].安徽医科大学学报，2025, 60(2):234-239. DOI:10.19405/j. cnki. issn1000-1492.2025.02.007.
[45]Ma N, Li X, Wei H, et al. Circular RNA circNFATC3acts as a miR-9-5p sponge to promote cervical cancer development by upregulating SDC2[J]. Cell Oncol(Dordr), 2021, 44(1):93-107.DOI:10.1007/s13402-020-00555-z.
[46]夏莹子，刘建刚，孙佳星，等.宫颈癌中SLC7A11、SDC2表达与临床病理特征及放疗敏感性的相关性[J].中国优生与遗传杂志，2025, 33(1):118-123.DOI:10.13404/j.cnki.cjbhh.2025.01.012.
[47]Mytilinaiou M, Bano A, Nikitovic D, et al. Syndecan-2is a key regulator of transforming growth factor beta 2/Smad2-mediated adhesion in fibrosarcoma cells[J].IUBMB Life, 2013, 65(2):134-143. DOI:10.1002/iub.1112.
[48]Péterfia B, Füle T, Baghy K, et al. Syndecan-1 enhances proliferation, migration and metastasis of HT-1080 cells in cooperation with syndecan-2[J]. PLoS One, 2012, 7(6):e39474. DOI:10.1371/journal.pone.0039474.
[49]Park H, Han I, Kwon HJ, et al. Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells[J]. Cancer Res, 2005, 65(21):9899-9905. DOI:10.1158/0008-5472. Can-05-1386.
[50]Zhang Z, Cui F, Zhou M, et al. Single-cell RNA sequencing analysis identifies key genes in brain metastasis from lung adenocarcinoma[J]. Curr Gene Ther, 2021, 21(4):338-348. DOI:10.2174/1566523221666210319104752.
[51]Tsoyi K, Osorio JC, Chu SG, et al. Lung adenocarcinoma syndecan-2 Potentiates cell invasiveness[J]. Am J Respir Cell Mol Biol, 2019, 60(6):659-666. DOI:10.1165/rcmb.2018-0118OC.
[52]Munesue S, Kusano Y, Oguri K, et al. The role of syndecan-2 in regulation of actin-cytoskeletal organization of Lewis lung carcinoma-derived metastatic clones[J]. Biochem J, 2002, 363(Pt 2):201-209.DOI:10.1042/0264-6021:3630201.
[53]Oto J, Le QK, Sch?fer SD, et al. Role of syndecans in ovarian cancer:new diagnostic and prognostic biomarkers and potential therapeutic targets[J]. Cancers(Basel),2023, 15(12):3125. DOI:10.3390/cancers 15123125.
[54]De Oliveira T, Abiatari I, Raulefs S, et al. Syndecan-2promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype[J].Mol Cancer, 2012, 11:19. DOI:10.1186/1476-4598-11-19.
[55]Hrabar D, Aralica G, Gomercic M, et al. Epithelial and stromal expression of syndecan-2 in pancreatic carcinoma[J]. Anticancer Res, 2010, 30(7):2749-2753.
[56]Wang B, Zhu Y, Zhang X, et al. Identification and validation of a glycolysis-related gene signature for predicting metastasis and survival rate in patients with thyroid cancer[J]. Transl Cancer Res, 2023, 12(5):1100-1111. DOI:10.21037/tcr-22-2548.
[57]Wang X, Peng W, Li C, et al. Identification of an immune-related signature indicating the dedifferentiation of thyroid cells[J]. Cancer Cell Int, 2021, 21(1):231.DOI:10.1186/s12935-021-01939-3.
[58]Popovi?A, Demirovi?A, Spaji?B, et al. Expression and prognostic role of syndecan-2 in prostate cancer[J].Prostate Cancer Prostatic Dis, 2010, 13(1):78-82.DOI:10.1038/pcan.2009.43.
[59]Meng F, Han X, Min Z, et al. Prognostic signatures associated with high infiltration of Tregs in bone metastatic prostate cancer[J]. Aging(Albany NY), 2021, 13(13):17442-17461. DOI:10.18632/aging. 203234.
[60]Santos NJ, Barquilha CN, Barbosa IC, et al. Syndecan family gene and protein expression and their prognostic values for prostate cancer[J]. Int J Mol Sci, 2021, 22(16):8669. DOI:10.3390/ijms22168669.
[61]García-Suárez O, García B, Fernández-Vega I, et al.Neuroendocrine tumors show altered expression of chondroitin sulfate, glypican 1, glypican 5, and syndecan 2 depending on their differentiation grade[J].Front Oncol, 2014, 4:15. DOI:10.3389/fonc. 2014.00015.
[62]Ye Z, Huang N, Fu Y, et al. Tumor purity-related genes for predicting the prognosis and drug sensitivity of DLBCL patients[J]. Elife, 2024, 13:RP92841. DOI:10.7554/eLife.92841.
[63]谢祖成，陈馨蕊，石远凯.弥漫大B细胞淋巴瘤治疗耐药研究进展[J].中国肿瘤临床与康复，2023, 30(9):539-547.DOI:10.13455/j.cnki.cjcor.113494-20231017-0153.
基本信息:
DOI：10.13455/j.cnki.cjcor.113494-20250703-0258
中图分类号:R730.2
引用信息:
[1]田荣乐,崔菲菲,叶振邦,等.Syndecan-2基因与肿瘤研究进展[J].中国肿瘤临床与康复,2025,32(12):745-755.DOI:10.13455/j.cnki.cjcor.113494-20250703-0258.
基金信息:
中国医学科学院肿瘤医院深圳医院院内科研课题(E010224012)~~
2025-12-28
2025-12-28